Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Serum myostatin levels are associated with physical function and hospitalization in peritoneal dialysis patients

Abstract

Background

Myostatin functions as a negative regulator of skeletal muscle growth. The association of myostatin with muscle parameters in dialysis patients is inconsistent, and there are no studies associating myostatin with physical function and outcomes in peritoneal dialysis (PD) patients. Therefore, we assessed the association of serum myostatin with lean mass, physical function, and hospitalization in a prospective cohort of PD patients.

Methods

Lean mass, physical function, and serum myostatin were assessed at baseline. Patients were followed up for at least 24 months and hospitalization was recorded.

Results

Serum myostatin levels were positively correlated with handgrip strength and Appendicular Lean Mass Index among male patients. Binary logistic regression models were performed including myostatin levels and physical function parameters as independent variables. Serum myostatin, handgrip strength, gait speed, and Short Physical Performance Battery were associated with hospitalization.

Conclusion

Lower serum myostatin and physical function were associated with hospitalization in PD patients.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Data availability

All data generated or analyzed during this study are included in this published article.

References

  1. McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature. 1997;387:83–90. https://doi.org/10.1038/387083a0

    Article  CAS  PubMed  Google Scholar 

  2. Baczek J, Silkiewicz M, Wojszel ZB. Myostatin as a biomarker of muscle wasting and other pathologies-state of the art and knowledge gaps. Nutrients. 2020;12:2401. https://doi.org/10.3390/nu12082401

    Article  CAS  PubMed Central  Google Scholar 

  3. Bataille S, Chauveau P, Fouque D, Aparicio M, Koppe L. Myostatin and muscle atrophy during chronic kidney disease. Nephrol Dial Transplant. 2020:gfaa129. https://doi.org/10.1093/ndt/gfaa129.

  4. Delanaye P, Bataille S, Quinonez K, Buckinx F, Warling X, Krzesinski JM, et al. Myostatin and insulin-like growth factor 1 are biomarkers of muscle strength, muscle mass, and mortality in patients on hemodialysis. J Ren Nutr. 2019;29:511–20. https://doi.org/10.1053/j.jrn.2018.11.010

    Article  CAS  PubMed  Google Scholar 

  5. Lee SM, Kim SE, Lee JY, Jeong HJ, Son YK, An WS. Serum myostatin levels are associated with abdominal aortic calcification in dialysis patients. Kidney Res Clin Pract. 2019;38:481–9. https://doi.org/10.23876/j.krcp.19.019

    Article  PubMed  PubMed Central  Google Scholar 

  6. Yamada S, Tsuruya K, Yoshida H, Tokumoto M, Ueki K, Ooboshi H, et al. Factors associated with the serum myostatin level in patients undergoing peritoneal dialysis: potential effects of skeletal muscle mass and vitamin Dreceptor activator use. Calcif Tissue Int. 2016;99:13–22. https://doi.org/10.1007/s00223-016-0118-6

    Article  CAS  PubMed  Google Scholar 

  7. Silva MZC, Vogt BP, Reis NSC, Caramori JCT. Update of the European consensus on sarcopenia: what has changed in diagnosis and prevalence in peritoneal dialysis? Eur J Clin Nutr. 2019;73:1209–11. https://doi.org/10.1038/s41430-019-0468-z

  8. Bergen HR, Farr JN, Vanderboom PM, Atkinson EJ, White TA, Singh RJ, et al. Myostatin as a mediator of sarcopenia versus homeostatic regulator of muscle mass: insights using a new mass spectrometry-based assay. Skelet. Muscle. 2015;15:21. https://doi.org/10.1186/s13395-015-0047-5.

    Article  CAS  Google Scholar 

  9. Zhou Y, Hellberg M, Hellmark T, Hoglund P, Clyne N. Muscle mass and plasma myostatin after exercise training: a substudy of Renal Exercise (RENEXC)—a randomized, controlled trial. Nephrol Dial Transpl. 2021;36:95–103. https://doi.org/10.1093/ndt/gfz210

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Contributions

MZCS, BPV, and MFM were responsible for conceptualization and methodology; MZCS, NSCR, FCM, and MSD performed data acquisition; MZCS, BPV, and MFM performed data analysis and interpretation, were involved in formal analysis and wrote the original draft; MZCS, BPV, NSCR, FCM, MSD, MFM, and JCTC revised and edited the manuscript; JCTC, MFM, and BPV were responsible for supervision and mentorship. All authors provided intellectual content of critical importance to the work and gave final approval for the version to be published.

Corresponding author

Correspondence to Jacqueline Costa Teixeira Caramori.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Silva, M.Z.C., Vogt, B.P., Reis, N.S.C. et al. Serum myostatin levels are associated with physical function and hospitalization in peritoneal dialysis patients. Eur J Clin Nutr (2022). https://doi.org/10.1038/s41430-022-01227-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1038/s41430-022-01227-x

Search

Quick links